Abstract
Background Male hypogonadism arises from a deficiency in testosterone secretion that may occur naturally with increasing age, or as a result of malfunction of the hypothalamus, pituitary gland or testes. Tostran ® (also known as Fortigel ®, Itnogen ® and Tostrex ®) is a metered-dose gel formulation of 2% testosterone that was recently developed to treat male hypogonadism and to overcome the disadvantages exhibited by some testosterone formulations. Methods A prospective Phase II trial of Tostran in men with primary or secondary hypogonadism evaluating the effect of showering was conducted. Results This trial demonstrated that showering 2 h after application of Tostran has no significant effect on serum testosterone levels. Conclusion Market research in the UK and Germany has indicated that endocrinologists would consider switching patients to Tostran from other formulations, especially other gels. Their preference is due to the dosage and administration advantages of Tostran, the flexibility of the metered-dose formulation, and the ability to shower 2 h after application.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
